CR9839A - Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica - Google Patents

Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica

Info

Publication number
CR9839A
CR9839A CR9839A CR9839A CR9839A CR 9839 A CR9839 A CR 9839A CR 9839 A CR9839 A CR 9839A CR 9839 A CR9839 A CR 9839A CR 9839 A CR9839 A CR 9839A
Authority
CR
Costa Rica
Prior art keywords
composition containing
cheratitis
herpetic
treatment
pharmaceutical composition
Prior art date
Application number
CR9839A
Other languages
English (en)
Inventor
Wihsmann Marc
Schmitz Reinhard
Original Assignee
Berlin Chemie Ag
Candida Aurora Pereira Dieguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag, Candida Aurora Pereira Dieguez filed Critical Berlin Chemie Ag
Publication of CR9839A publication Critical patent/CR9839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composicion Oftalmologica que contiene de 0,05 a 0,3% w/w de brivudina como ingrediente activo y la formacion de una pelicula de agentes seleccionados de entre el grupo consistente en pyrrolidone de polivinilo (PVP), alcohol de polivinilo (PVA) y polyacrylate (PA).
CR9839A 2005-09-29 2008-03-27 Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica CR9839A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005046769A DE102005046769A1 (de) 2005-09-29 2005-09-29 Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)

Publications (1)

Publication Number Publication Date
CR9839A true CR9839A (es) 2008-10-31

Family

ID=37561306

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9839A CR9839A (es) 2005-09-29 2008-03-27 Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica

Country Status (33)

Country Link
US (1) US20080249061A1 (es)
EP (1) EP1940353B1 (es)
JP (1) JP2009509993A (es)
KR (1) KR20080053319A (es)
CN (1) CN101272765A (es)
AP (1) AP2008004394A0 (es)
AR (1) AR056551A1 (es)
AT (1) ATE489076T1 (es)
AU (1) AU2006299115A1 (es)
BR (1) BRPI0616449A2 (es)
CA (1) CA2624111A1 (es)
CR (1) CR9839A (es)
CY (1) CY1111059T1 (es)
DE (2) DE102005046769A1 (es)
DK (1) DK1940353T3 (es)
EA (1) EA012975B1 (es)
EC (1) ECSP088310A (es)
ES (1) ES2356774T3 (es)
HN (1) HN2008000497A (es)
HR (1) HRP20110085T1 (es)
IL (1) IL190466A0 (es)
MA (1) MA29887B1 (es)
NO (1) NO20081488L (es)
PE (1) PE20070767A1 (es)
PL (1) PL1940353T3 (es)
PT (1) PT1940353E (es)
RS (1) RS51615B (es)
SI (1) SI1940353T1 (es)
TN (1) TNSN08094A1 (es)
TW (1) TW200744664A (es)
UA (1) UA90911C2 (es)
WO (1) WO2007039201A2 (es)
ZA (1) ZA200802729B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A2 (en) * 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
WO2009100367A2 (en) * 2008-02-06 2009-08-13 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
RS58731B1 (sr) 2014-01-22 2019-06-28 Visufarma B V Kompozicija koja sadrži jota-karagenan protiv virusnog konjuktivitisa
TWI738774B (zh) * 2016-05-06 2021-09-11 美商沙希公司 眼用組成物
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen

Also Published As

Publication number Publication date
ES2356774T3 (es) 2011-04-13
CA2624111A1 (en) 2007-04-12
CY1111059T1 (el) 2015-06-11
AU2006299115A1 (en) 2007-04-12
WO2007039201A3 (en) 2007-10-04
WO2007039201A2 (en) 2007-04-12
NO20081488L (no) 2008-03-26
MA29887B1 (fr) 2008-10-03
DE102005046769A1 (de) 2007-04-05
HRP20110085T1 (hr) 2011-03-31
KR20080053319A (ko) 2008-06-12
PT1940353E (pt) 2011-02-25
RS51615B (en) 2011-08-31
PL1940353T3 (pl) 2011-05-31
EA012975B1 (ru) 2010-02-26
PE20070767A1 (es) 2007-08-13
ATE489076T1 (de) 2010-12-15
AR056551A1 (es) 2007-10-10
TNSN08094A1 (en) 2009-07-14
IL190466A0 (en) 2008-11-03
CN101272765A (zh) 2008-09-24
UA90911C2 (ru) 2010-06-10
ECSP088310A (es) 2008-05-30
DK1940353T3 (da) 2011-01-24
TW200744664A (en) 2007-12-16
JP2009509993A (ja) 2009-03-12
BRPI0616449A2 (pt) 2011-06-21
US20080249061A1 (en) 2008-10-09
EA200800646A1 (ru) 2008-10-30
EP1940353B1 (en) 2010-11-24
DE602006018505D1 (de) 2011-01-05
HN2008000497A (es) 2010-09-10
SI1940353T1 (sl) 2011-03-31
EP1940353A2 (en) 2008-07-09
ZA200802729B (en) 2009-09-30
AU2006299115A2 (en) 2008-05-29
AP2008004394A0 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
CR9839A (es) Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
UY30759A1 (es) Compuestos quimicos
AR044131A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
CL2008003326A1 (es) Compuestos derivados de [(2r)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil]hidroxiformamida, formas polimorficas 1, 2 y 3 de dichos compuestos; composicion farmaceutica; y su uso en el tratamiento de una enfermedad bacteriana del oido, sinusitis, infeccion del tracto respiratorio superior, entre otras.
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
CL2008002798A1 (es) Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
PE20060868A1 (es) Sales de aminio de 1,2,3- triazoles como profarmacos que incluyen agentes antivirales
ES2582871T3 (es) Composición terapéutica aromatizada basada en arcilla
CL2007003451A1 (es) Composicion farmaceutica solida oral que comprende un principio activo y polivinilpirrolidona (pvp) entre 1,0-25%, cpaa entre 0,5-10%, el principio activo consiste en una sal hidrosoluble de metal alcalino, de metal alcalino-terreo, una sal de mezcla
AR048432A1 (es) Composiciones diureticas de liberacion prolongada
AR078242A1 (es) Composicion y proceso para el tratamiento de un genero
UY27596A1 (es) Formulación oral de fludara purísimo con liberación rátida del ingrediente
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства
ES2421520T3 (es) Potenciador de la producción de adiponectina
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
AR078167A1 (es) Dispersion solida que comprende un agente anti-vih
CL2008001536A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente antimicrobiano como ciprofloxacino y un agente antioxidante como acido ascorbico, la concentracion de ciprofloxacino va desde 250 mg hasta 1 gr y desde 50 mg hasta 200 mg para acido ascorbico, en una unidad de dosis; y uso en infecciones urinarias.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)